Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Safety of VEGF-targeted tyrosine kinase inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) and central nervous system (CNS) metastases

Safety of VEGF-targeted tyrosine kinase inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) and central nervous system (CNS) metastases. ASCO meeting. 2007; [Poster Discussion]..


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.